Net sales fell 3% year-over-year in H1 2025, with Q2 EBITDA and net profit down sharply due to one-off costs and weaker Vinga Group performance. Chemgroup showed strong sales growth, while cash flow improved significantly. Management expects a stronger H2.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.